Appendix 4E and 2024 Annual Report
Filed with ASX · · 72 pages · English
Summary by 6ix AI
The report indicates that the Group experienced a loss after tax, with total income derived primarily from research and development tax incentives and interest income. Additionally, the report notes that no dividends were declared or paid during the financial year. The annual report includes insights from the Chairman, highlighting challenges and advancements in the development of their therapeutic antibodies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Patrys
- Further update on PAT-DX1 GMP manufacturing run
- Appendix 4C - Quarterly - 30 June 2024
- Update on GMP manufacturing run of PAT-DX1
- Appendix 4C - Quarterly - 31 March 2024
- Positive preclinical data for deoxymabs in vasculitis
Later from Patrys
- PAT-DX1 GMP specification testing update
- PAT-DX1 clinical development update
- Appendix 4C - Quarterly - 30 September 2024
- Appendix 4C - Quarterly - 31 December 2024
- Appendix 4D - Half Year Accounts - 31 December 2024
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys